Clinical Trial Update: Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pharmacodynamics and safety of patiromer in children and adolescents with chronic kidney disease and hyperkalemia; study terminated wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperkalemia

Drugs mentioned

• Patiromer (patiromer)

Snippet

Sponsor: Vifor Pharma, Inc. | Conditions: Hyperkalemia | Phase 2 | Status: TERMINATED | Results posted: 2022-09-26